Quality of life study for HHT patients
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This study looks at how hereditary hemorrhagic telangiectasia (HHT) affects your day-to-day life and well-being. By joining, you'll answer questions to help doctors better understand the impact of the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with HHT using standard criteria or a genetic test.
- You can understand and speak German.
- You are able to give your informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.
This study uses an echocardiogram (a heart ultrasound) to look for possible heart problems in people with hereditary hemorrhagic telangiectasia (HHT). It will help doctors understand how HHT affects the heart.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This study uses surveys to understand how HHT affects the quality of life of children and young adults. It may help improve care and support for patients and their families.
This study reviews past medical records (case notes) from people with hereditary hemorrhagic telangiectasia (HHT). It helps researchers understand patterns of care and outcomes, without requiring new treatment for you.
Hear when a new Hereditary Hemorrhagic Telangiectasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.